A copy of the message that follows will be sent to the addresses you specify:
Monthly e-Newsletter of The ALS Association
February 2016
ALS Patients at Center of Groundbreaking Effort to Speed Approval of New Treatments
The ALS Association has launched a groundbreaking initiative to create a patient-focused drug development guidance that is designed to accelerate the development of therapies to slow or stop ALS. The guidance, which will be submitted to the Food and Drug Administration (FDA) this spring, will serve as a roadmap to help the pharmaceutical industry navigate the development process and provide the FDA with an ALS community-centered view of how it should approach therapies for ALS.
Save the date: National ALS Advocacy Day & Public Policy Conference
Registration for this year’s National ALS Advocacy Day & Public Policy Conference opens next Monday, February 8! Will you join us this May in Washington, DC to spread ALS awareness on Capitol Hill and urge Congress to do more in the fight against ALS? On February 8, visit www.alsa.org/advocacy to sign up!
When you participate in the Walk to Defeat ALS®, you help raise millions of dollars to support people affected by ALS; fund collaborative ALS research; and advocate for legislation that is important to the ALS community. It’s time to rally your team and raise funds that are critical to advance the fight against ALS!
Meet the Yoakum Family: Support like yours makes a difference in their lives!
ALS runs in the Yoakum family. Sadly, Rachel lost her grandfather to ALS in 2007. Now, she helps care for her father, Jim, who is battling the disease. Jim is confined to his wheelchair, presenting many challenges to daily living.
An enthusiastic Star Wars fan, Jim’s heart was set on seeing Star Wars: The Force Awakens in theaters. Because the Yoakum family does not own a van equipped to transport Jim in his wheelchair, traveling is difficult. But, Rachel didn’t let that deter her.
Read how support from people like you fulfilled Jim’s dream of going to the movies last month!
A Phase II Study in ALS of the Effects of Mexiletine on Hyperexcitability of Motor Neurons
Thursday, February 11, 2016
11 a.m. Pacific Standard Time
(2 p.m. Eastern Standard Time)
Modeling C9orf72 disease: a crucial step for therapeutic development in ALS
Wednesday, March 2, 2016
1 p.m. Pacific Standard Time
(4 p.m. Eastern Standard Time)